Lutris Pharma Announces Publication of Positive Data From Its Phase 1 / 2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer

Lutris Pharma Israel California New York

View original content:https://www.prnewswire.co.uk/news-releases/lutris-pharma-announces-publication-of-positive-data-from-its-phase-12-trial-of-lut014-to-treat-radiation-dermatitis-in-patients-with-breast-cancer-302066543.html